Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01426958
First received: August 30, 2011
Last updated: June 3, 2014
Last verified: October 2013
  Purpose

To study the effect of the P-glycoprotein inhibitor ritonavir on the pharmacokinetics (PK) of afatinib depending on the timepoint of ritonavir administration


Condition Intervention Phase
Healthy
Drug: afatinib
Drug: ritonavir + afatinib
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Relative Bioavailability of a Single Oral Dose of 40 mg Afatinib Given Alone Compared to Concomitant and Timed Administration of Multiple Oral Doses of Ritonavir - an Open-label, Randomised, Three-way Crossover Trial in Healthy Male Volunteers

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Area Under Curve From 0 to tz (AUC0-tz) [ Time Frame: 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96, 120 hours post ] [ Designated as safety issue: No ]
    AUC0-tz represents the area under the concentration curve of the analyte in plasma from 0 to the time of the last quantifiable plasma contentration of the analyte.

  • Maximum Concentration (Cmax) [ Time Frame: 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96, 120 hours post ] [ Designated as safety issue: No ]
    Cmax represents the maximum concentration of the analyte in plasma.

  • Area Under Curve From 0 to ∞ Hours (AUC0-∞) [ Time Frame: 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96, 120 hours post ] [ Designated as safety issue: No ]
    AUC0-∞ represents the area under the concentration curve of the analyte in plasma from 0 extrapolated to infinity.


Enrollment: 24
Study Start Date: August 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: treatment A
1 tablet afatinib single dose
Drug: afatinib
standard therapeutic dose
Experimental: treatment B
2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day
Drug: ritonavir + afatinib
simultaneous intake of ritonavir and afatinib on second treatment day
Experimental: treatment C
2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day
Drug: ritonavir + afatinib
on the second treatment day the first ritonavir tablet will be taken 6 hours after the afatinib tablet

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

1. healthy male subjects

Exclusion criteria:

1. any relevant deviation from healthy conditions

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01426958

Locations
Germany
1200.151.1 Boehringer Ingelheim Investigational Site
Biberach, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Additional Information:
No publications provided

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01426958     History of Changes
Other Study ID Numbers: 1200.151, 2011-001803-11
Study First Received: August 30, 2011
Results First Received: August 8, 2013
Last Updated: June 3, 2014
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
United States: Food and Drug Administration

Additional relevant MeSH terms:
Ritonavir
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 28, 2014